Justices Mull Drug Disclosures In Matrixx Fraud Case
The U.S. Supreme Court on Monday weighed the implications of companies disclosing rare or dubious claims of drug side effects to shareholders, battering attorneys for the plaintiffs and Matrixx Initiatives Inc....To view the full article, register now.
Already a subscriber? Click here to view full article